Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.61 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | RARB | P10826 | 2/20 | 0.45 |
| ▸ | RARA | P10276 | 1/20 | 0.45 |
| ▸ | RARG | P13631 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28164754 | 0.98 | CSNK2A1 (0.59) | CSNK2A1NOTUMMEN1KMT2AALDH1A1 | |
| SCHEMBL31011348 | 0.87 | CSNK2A1 (0.61) | CSNK2A1NOTUMMEN1KMT2AALDH1A1 | |
| SCHEMBL87104 | 0.87 | CSNK2A1 (0.61) | CSNK2A1NOTUMMEN1KMT2AALDH1A1 | |
| SCHEMBL5597538 | 0.85 | CSNK2A1 (0.59) | CSNK2A1NOTUMMEN1KMT2AALDH1A1 | |
| SCHEMBL9726681 | 0.84 | CSNK2A1 (0.47) | CSNK2A1MEN1KMT2AALDH1A1LOXL2 | |
| SCHEMBL10052771 | 0.84 | MCL1 (0.61) | CSNK2A1RARBRARARARGMCL1 | |
| SCHEMBL467550 | 0.84 | CSNK2A1 (0.68) | CSNK2A1NOTUMMEN1KMT2AALDH1A1 | |
| SCHEMBL31627797 | 0.84 | CSNK2A1 (0.68) | CSNK2A1NOTUMMEN1KMT2AALDH1A1 | |
| SCHEMBL29688899 | 0.83 | KMT2A (0.46) | CSNK2A1MEN1KMT2AALDH1A1LOXL2 | |
| SCHEMBL1226712 | 0.83 | KMT2A (0.46) | CSNK2A1MEN1KMT2AALDH1A1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 827 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114507159-B | Preparation method of 4- [3 (E) -pentene-1-yl ] benzoate liquid crystal monomer | 中节能万润股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| CN-116836081-A | Ether epoxy toughening agent and preparation method and application thereof | 中国林业科学研究院林产化学工业研究所 | 2023-10-03 | — | — | CN | claimed |
| CN-116396159-A | Synthesis method of 2,2' -biphenyl dicarboxylic acid compound | 湖南大学 | 2023-07-07 | — | — | CN | claimed |
| CN-114685536-B | Binuclear cadmium complex with anticancer activity and preparation method and application thereof | 中山职业技术学院 | 2022-09-02 | — | — | CN | claimed |
| CN-114507159-A | Preparation method of 4- [3(E) -penten-1-yl ] benzoate liquid crystal monomer | 中节能万润股份有限公司 | 2022-05-17 | — | — | CN | claimed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| CN-110903182-A | Simple and environment-friendly chemical synthesis method of 4-fluoro-2-methylbenzoic acid | 北京艾德旺科技发展有限公司 | 2020-03-24 | — | — | CN | claimed |
| CN-110903176-A | Chemical synthesis method of 4-fluoro-2-methylbenzoic acid | 北京艾德旺科技发展有限公司 | 2020-03-24 | — | — | CN | claimed |
| CN-110343070-A | A kind of Antitubulin and the preparation method and application thereof | 山东大学 | 2019-10-18 | — | — | CN | claimed |
| CN-110088108-A | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-02 | — | — | CN | claimed |
| CN-109438418-A | Apoptosis signal regulating kinase inhibitor | 吉利德科学公司 | 2019-03-08 | — | — | CN | claimed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025224249-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| US-20250282746-A1 | HALOGEN-SUBSTITUTED ISOINDOLINE COMPOUND AND USE THEREOF | Chengdu Fendi Pharmaceutical Co., Ltd. (CN) | 2025-09-11 | — | — | US | disclosed |
| CN-1214048-A | Benzopyran derivatives having leukotriene-antagonistic action | LABROATORIOS MENARINI S A (ES) | 1999-04-14 | — | — | CN | disclosed |
| EP-0061907-B1 | SECONDARY AMINES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | BEECHAM GROUP PLC (GB) | 1984-08-01 | — | — | EP | disclosed |
| EP-0061907-A1 | Secondary amines, their preparation, pharmaceutical compositions containing them and their use | BEECHAM GROUP PLC (GB) | 1982-10-06 | — | — | EP | disclosed |
| US-4046905-A | Anti-inflammatory, analgesic and antipyretic phenylacetic acids | MERCK & CO., INC. (US) | 1977-09-06 | — | — | US | disclosed |
| US-3947582-A | Phenylacetic acid compounds in treating abnormal platelet aggregation | MERCK & CO., INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282746-A1 | HALOGEN-SUBSTITUTED ISOINDOLINE COMPOUND AND USE THEREOF | FLI1, CYP3A7, GTF2I | CSNK2A1 1544/4885NOTUM 2086/4885MEN1 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.